Instead of titrating to the full doses recommended for obesity treatment (e.g., semaglutide 2.4 mg weekly or tirzepatide up to 15 mg), microdosing involves starting and staying at much lower doses sometimes as low as 0.1 to 0.25 mg per week for semaglutide or even intermittent use
Es solo el sntoma de tu enfermedad, que es el exceso de peso que ha sido manejado, tratado, como quieras llamarlo, por la operacin
Such effects are consistent with their established reduction in atherosclerotic cardiovascular events and may be particularly relevant in patients with obesity, insulin resistance, or HFpEF phenotypes, and taken together, these mechanistic differences provide a biologically plausible rationale for combination therapy: SGLT2 inhibitors primarily target HF-related hemodynamic and cardiorenal pathways, whereas GLP-1 receptor agonists may further improve metabolic and vascular risk
Originally designed to treat type 2 diabetes, these "weight loss injections" are now being explored for their broader metabolic benefits
Yu J, Luo Y, Zhu Z, Zhou Y, Sun L, Gao J, et al
Individual results vary based on starting weight, adherence, and lifestyle factors